Literature DB >> 68920

Non-precipitating guinea-pig antibodies as products of limited recognition of antigenic sites on the ovalbumin molecule.

K Tamoto, J Koyama.   

Abstract

The non-precipitating guinea-pig IgG1 and IgG2 antibodies, produced by administration of an excessive dose of hen ovalbumin (OA), were capable of forming only certain soluble complexes having molar ratios of antibody to antigen lower than 1-5:1, which were lower than the minimum ratio of 2-5:1 shown by anti-OA antibodies precipitable with OA. This unusual property of the non-precipitating antibodies was caused by a limited number of antibody molecules capable of binding to one OA molecule simultaneously, since the maximum number of their Fab' fragments binding to one OA molecule was only three and markedly less than the number (7-8) of Fab' fragments of the precipitating IgG1 and IgG2 anti-OA antibodies binding to one OA molecule. These results demonstrate that the non-precipitating IgG1 and IgG2 anti-OA antibodies are those reacting with some particular antigenic sites on OA, a number of the antigenic sites too few to permit insoluble lattice formation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 68920      PMCID: PMC1445105     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  14 in total

1.  Non-precipitating rabbit antibodies: a study of their reactivity in vitro by means of the quantitative precipitin and tannic acid haemagglutination techniques.

Authors:  L G FISET
Journal:  Immunology       Date:  1962-09       Impact factor: 7.397

2.  Effect of iodination on the active site of several antihapten antibodies.

Authors:  A L GROSSBERG; G RADZIMSKI; D PRESSMAN
Journal:  Biochemistry       Date:  1962-05-25       Impact factor: 3.162

3.  Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds.

Authors:  A NISONOFF; F C WISSLER; L N LIPMAN; D L WOERNLEY
Journal:  Arch Biochem Biophys       Date:  1960-08       Impact factor: 4.013

4.  Biological activities of aggregated gamma globulin. I. Skin reactive and complement-fixing properties of heat denatured gamma globulin.

Authors:  T ISHIZAKA; K ISHIZAKA
Journal:  Proc Soc Exp Biol Med       Date:  1959 Aug-Sep

5.  The effect of complements on soluble antigen-antibody complexes.

Authors:  W O WEIGLE; P H MAURER
Journal:  J Immunol       Date:  1957-09       Impact factor: 5.422

6.  [Coexistence of precipitating and non-precipitating complexes in the interaction of human serum albumin and specific horse immune sera; quantitative deductions and theoretical implications].

Authors:  P BURTIN
Journal:  Bull Soc Chim Biol (Paris)       Date:  1955

7.  Purification and properties of non-precipitating rabbit antibodies.

Authors:  R Margni; R Binaghi
Journal:  Immunology       Date:  1972-04       Impact factor: 7.397

8.  Effect of varying the immunizing dose of ovalbumin on the production of non-precipitating IgG1 and IgG2 antibodies in guinea pigs.

Authors:  T Nakamura; T Okawa; J Koyama
Journal:  J Biochem       Date:  1973-07       Impact factor: 3.387

9.  Non-precipitating guinea-pig antibodies produced by administration of excessive doses of ovalbumin.

Authors:  K Tamoto; T Nakamura; J Koyama
Journal:  Immunology       Date:  1974-03       Impact factor: 7.397

10.  Character of non-precipitating antibodies.

Authors:  C L Christian
Journal:  Immunology       Date:  1970-04       Impact factor: 7.397

View more
  2 in total

1.  Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids.

Authors:  H Takeya; T Mori; E C Gabazza; K Kuroda; H Deguchi; E Matsuura; K Ichikawa; T Koike; K Suzuki
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

2.  In vivo glucocorticoid modulation of guinea pig splenic macrophage Fc gamma receptors.

Authors:  P Ruiz; F Gomez; M King; R Lopez; C Darby; A D Schreiber
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.